Vanguards of Health Care by Bloomberg Intelligence Podcast By Bloomberg cover art

Vanguards of Health Care by Bloomberg Intelligence

Vanguards of Health Care by Bloomberg Intelligence

By: Bloomberg
Listen for free

Vanguards of Health Care is a series of exclusive conversations with management teams and thought leaders discussing changes on the forefront of the industry, including innovations in medical products and technologies, advances in clinical research, new service models, wellness and regulations.

2026 Bloomberg
Economics Hygiene & Healthy Living Personal Finance
Episodes
  • Abridge Moving AI From Scribing to Clinical Workflows
    Mar 26 2026

    “I think 2026 is the year of fundamental, agentic transformation of the workflow.” Abridge co-founder and CTO Zack Lipton joins Bloomberg Intelligence analyst Jonathan Palmer to share how the company grew from a research-heavy idea into one of health care’s breakout AI leaders. Lipton breaks down the limits of point solutions, the complexity of evaluating generative AI in medicine, and why he sees the future not as a better digital scribe alone, but as a unified platform that can guide documentation, billing and care decisions in real time.

    See omnystudio.com/listener for privacy information.

    Show more Show less
    52 mins
  • 7Wire's Jaffee on the Hard Truths Behind Health-Tech Investing
    Mar 19 2026

    “In health care, in order to drive the biggest impact, the biggest outcomes and the biggest exits, you really have to engage the end consumer,” says Alyssa Jaffee, partner at 7Wire Ventures. In this Vanguards of Health Care episode, Jaffee sits down with Bloomberg Intelligence analyst Jonathan Palmer to discuss 7Wire’s thesis-driven approach to venture investing, how the firm works shoulder to shoulder with founders and why health care still offers endless opportunities to fix broken systems. She also reflects on women’s health, the evolving AI landscape and the personal values — integrity, work ethic and mission — that shape how she invests and leads.

    See omnystudio.com/listener for privacy information.

    Show more Show less
    42 mins
  • Xaira’s War on Trial-and-Error Drug Development
    Mar 12 2026

    “Nothing excites me as much as the potential for AI,” Xaira CEO Marc Tessier-Lavigne tells Bloomberg Intelligence analyst Sam Fazeli on this episode of the Vanguards of Health Care podcast. They explore how artificial intelligence could cut drug development timelines in half and triple clinical success rates. Tessier-Lavigne, a former Genentech R&D leader, explains why today’s 13-year, 90% failure model is broken and how causal cell models, generative protein design and smarter patient stratification can transform target selection, drug creation and trials. Tessier-Lavigne also details why Xaira is chasing “high-hanging fruit,” the hard-to-drug targets others can’t reach, and what it will take to reverse Eroom’s Law.

    See omnystudio.com/listener for privacy information.

    Show more Show less
    53 mins
No reviews yet